• KOL
    • Herpes Zoster
    • John W Jr Gnann
    • John W Jr Gnann: Influence Statistics

      John W Jr Gnann

      John W Jr Gnann

      Show email address

      Department of Medicine, The Medical University of South Carolina University Medical Center, Charleston, South Carolina | Department of Infectious Diseases, College of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      John W Jr Gnann:Expert Impact

      Concepts for whichJohn W Jr Gnannhas direct influence:Herpes zoster,Zoster vaccine,West nile,Postherpetic neuralgia,Genital herpes,Prosthetic valve endocarditis,Vaccine efficacy,Zoster pain.

      John W Jr Gnann:KOL impact

      Concepts related to the work of other authors for whichfor which John W Jr Gnann has influence:Herpes zoster,Postherpetic neuralgia,Simplex virus,Neuropathic pain,Antiviral agents,United states,Viral infections.

      KOL Resume for John W Jr Gnann

      Year
      2021

      Department of Medicine, The Medical University of South Carolina University Medical Center, Charleston, South Carolina

      2018

      Department of Infectious Diseases, College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA

      2017

      Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina, 135 Rutledge Avenue, MSC 752, 29425, Charleston, SC, USA

      Emeritus Professor of Infectious Diseases, Brighton and Sussex Medical School, Brighton, UK

      2016

      Medical University of South Carolina, Charleston, SC

      2015

      Division of Infectious Diseases, Department of Internal Medicine, Medical University of South Carolina, Charleston, SC 29403, USA

      University of Alabama at Birmingham

      2014

      Medical University of South Carolina, Charleston, SC, USA

      2013

      Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham

      Medical University of South Carolina, Charleston

      2012

      Division of Infectious Diseases, University of Alabama of Birmingham and Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA.

      Birmingham Veterans Affairs Medical Center, Alabama

      2009

      Division of Infectious Diseases, Department of Pediatrics, the University of Alabama at Birmingham, Nashville, Tennessee

      Departments of Medicine, Pediatrics, and Microbiology, The University of Alabama at Birmingham and Birmingham VA Medical Center (Dr Gnann).

      Birmingham VA Medical Center, Birmingham, Alabama, USA

      2008

      Department of Medicine, Division of Infectious Diseases, University of Alabama, Birmingham

      2007

      Department of Medicine, The University of Alabama, Birmingham

      2006

      University of Alabama at Birmingham, Alabama

      2005

      Departments of Medicine and Pediatrics, University of Alabama at Birmingham and the Veterans Administration Medical Center, Birmingham, AL

      2004

      University of Alabama at Birmingham, Birmingham, AL, USA

      2003

      Departments of Medicine and Microbiology, University of Alabama at Birmingham and Birmingham Veteran's Administration Medical Center, Los Angeles

      2002

      Departments of Medicine and Microbiology, University of Alabama at Birmingham, 1600 7th Avenue South, ACC 616 Birmingham, Alabama, USA

      2001

      Department of Pediatrics, Children's Hospital, University of Alabama at Birmingham, 153 Wallace Tumor Institute, 1824 6th Avenue, S. Birmingham, Alabama 35294‐3300, U.S.A.

      2000

      University of Alabama at Birmingham, Alabama, Georgia

      1999

      Departments of Pediatrics, Microbiology and Medicine, The University of Alabama at Birmingham, 1600 Seventh Avenue South, 616 Children’s Hospital, Birmingham, AL 35233, USA

      1998

      Division of Infectious Diseases,

      1996

      The University of Alabama at Birmingham, Antiviral Research Office, 309 Bevil Biomedical Research Building, 845 Nineteenth Street South, Birmingham, AL 35294-2710 USA

      1994

      University of Alabama at Birmingham, Birmingham, AL

      1992

      From the Departments of Pediatrics (R.J.W.), Microbiology (R.J.W., J.W.G.), and Medicine (R.J.W., J.W.G.), University of Alabama at Birmingham, Birmingham. Address reprint requests to Dr. Whitley at 653 Children's Hospital Tower, 1600 Seventh Ave. S., Birmingham, AL 35294–0011.

      1991

      Departments of Medicine and Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA

      1990

      Department of Immunology, Scripps Clinic and Research Foundation, 10666 N. Torrey Pines Road, 92037, La Jolla, CA, USA

      1988

      Departments of Pediatrics and Medicine, University of Alabama at Birmingham, Birmingham, Alabama USA

      Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.

      1987

      Infectious Diseases Service, Department of Medicine, Madigan Army Medical Center, Tacoma, Washington USA

      1986

      From the Infectious Diseases Service, Department of Medicine, Madigan Army Medical Center, Tacoma, Wash.

      1983

      Departments of Medicine, Pediatrics and Microbiology, University of Alabama in Birmingham.

      1979

      Departments of Pediatrics and Microbiology, Duke University Medical Center, Durham, North Carolina

      Sign-in to see all concepts, it's free!
      Sample of concepts for which John W Jr Gnann is among the top experts in the world.
      Concept World rank
      bacteremia bites #1
      neurologic complications syndrome #1
      bw882c87 #1
      acute rash potential #1
      vzv retinitis persons #1
      primary exogenous contact #1
      disseminated herpes #1
      611 reduction #1
      sorivudine bw882c87 #1
      ceftriaxone vitro activity #1
      primary infection varicella #1
      vzvspecific cellmediated immune #1
      latent vzv herpes #1
      famciclovir prodrugs #1
      incidence postherpetic neuralgia #1
      investigational famciclovir #1
      unusual complications vzv #1
      665 reduction #1
      arabinofuranosyluracil drugs #1
      herpes zoster efforts #1
      reduction zoster #1
      persons current knowledge #1
      famciclovir famciclovir herpes #1
      variety neurologic complications #1
      incidence neuralgia #1
      zoster older adults #1
      older adults herpes #1
      new drugs activity #1
      variety persons #1
      recipients zoster #1
      incidence postherpetic #1
      declining varicellazoster virus #1
      evaluation valaciclovir #1
      herpes zoster variety #1
      disease chickenpox #1
      zoster including #1
      acyclovir neuralgia #1
      reactivation latent vzv #1
      prevent herpes zoster #1
      focused immunosuppressive #2
      omriggam #2
      pathological rationale #2
      Sign-in to see all concepts, it's free!

      Prominent publications by John W Jr Gnann

      KOL-Index: 15934

      BACKGROUND: The incidence and severity of herpes zoster and postherpetic neuralgia increase with age in association with a progressive decline in cell-mediated immunity to varicella-zoster virus (VZV). We tested the hypothesis that vaccination against VZV would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia among older adults.

      METHODS: We enrolled 38,546 adults 60 years of age or older in a randomized, double-blind, placebo-controlled trial of an ...

      Known for Herpes Zoster | Postherpetic Neuralgia | Vaccine Recipients | Burden Illness | Pain Discomfort
      KOL-Index: 13533

      BACKGROUND: Herpes zoster (HZ) adversely affects individuals aged 50-59, but vaccine efficacy has not been assessed in this population. This study was designed to determine the efficacy, safety, and tolerability of zoster vaccine for preventing HZ in persons aged 50-59 years.

      METHODS: This was a randomized, double-blind, placebo-controlled study of 22 439 subjects aged 50-59 years conducted in North America and Europe. Subjects were given 1 dose of licensed zoster vaccine (ZV) (Zostavax; ...

      Known for Zoster Vaccine | Persons Aged | 59 Years | North America | Incidence Hz
      KOL-Index: 10743

      Although acute pain in patients with herpes zoster can be severe and has a substantial impact on health-related quality of life, there have been no randomized clinical trials of oral medications specifically for its ongoing treatment. A randomized clinical trial was conducted in which 87 subjects >or=50 years of age with herpes zoster within 6 calendar days of rash onset and with worst pain in the past 24h >or=3 on a 0-10 rating scale initiated 7 days of treatment with famciclovir in ...

      Known for Acute Pain | Herpes Zoster | Gabapentin Placebo | Opioid Clinical Trials | Healthrelated Quality
      KOL-Index: 10495

      Herpes zoster causes substantial morbidity, especially among older adults. Although the acute cutaneous manifestations can be painful and troublesome, the most important consequence of herpes zoster (shingles) is the chronic pain syndrome known as postherpetic neuralgia (PHN). Previous studies have suggested that declining varicella-zoster virus (VZV)-specific cell-mediated immune (CMI) responses account for the increased frequency of herpes zoster seen in older adults. This led to the ...

      Known for Herpes Zoster | Postherpetic Neuralgia | Vaccine Recipients | Shingles Prevention Study | Randomized Controlled
      KOL-Index: 9761

      BACKGROUND: Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic cell transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown.

      METHODS: In a multicenter prospective trial, hematopoietic cell transplant recipients with respiratory syncytial virus infection of the upper airways were randomized to receive ribavirin (2 g 3 times daily) or supportive care for 10 days. The ...

      Known for Aerosolized Ribavirin | Syncytial Virus | Transplant Recipients | Respiratory Tract | Viral Load
      KOL-Index: 9610

      BACKGROUND: The Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination. A Short-Term Persistence Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years. A Long-Term Persistence Substudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvaccination. Study outcomes were assessed for the entire LTPS period and for each year from 7 to 11 years ...

      Known for Vaccine Efficacy | Incidence Hz | Zoster Herpes | 5 Years | Term Persistence
      KOL-Index: 8871

      Accurate evaluation of pain plays a critical role in identifying new interventions for the treatment and prevention of herpes zoster and postherpetic neuralgia (PHN). Different types of pain and other sensory symptoms are found in patients with herpes zoster, and these vary greatly with respect to their presence, location, duration, intensity, and quality. The results of recent studies of herpes zoster and PHN and the development of new methods for assessing neuropathic pain provide a ...

      Known for Herpes Zoster | Postherpetic Neuralgia | Neuropathic Pain | New Interventions | Treatment Prevention
      KOL-Index: 8328

      BACKGROUND: After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ).

      METHODS: A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed ...

      Known for Zoster Vaccine | Shingles Prevention Study | Aged 80 | Placebo Recipients | Female Herpes
      KOL-Index: 8120

      BACKGROUND: West Nile Virus (WNV) is a mosquito-borne flavivirus that has caused ongoing seasonal epidemics in the United States since 1999. It is estimated that ≤1% of WNV-infected patients will develop neuroinvasive disease (West Nile encephalitis and/or myelitis) that can result in debilitating morbidities and long-term sequelae. It is essential to collect longitudinal information about the recovery process and to characterize predicative factors that may assist in therapeutic ...

      Known for West Nile | Neuroinvasive Disease | Neurological Manifestations | Virus Wnv | Longterm Sequelae
      KOL-Index: 7466

      Varicella-zoster virus (VZV) is the etiologic agent of varicella (primary infection) and herpes zoster (reactivation of latent infection). Although varicella is most often a relatively benign and self-limited childhood illness, the disease can be associated with a variety of serious and potentially lethal complications in both immunocompetent and immunocompromised persons. One complication of varicella that appears to be increasing in frequency is serious bacterial soft tissue infections ...

      Known for Atypical Presentations | Zoster Virus | Neurologic Complications | Pregnant Women | Primary Infection

      Key People For Herpes Zoster

      Top KOLs in the world
      #1
      John W Jr Gnann
      herpes zoster postherpetic neuralgia vaccine efficacy
      #2
      Myron J Levin
      herpes zoster united states simplex virus
      #3
      Michael N Oxman
      herpes zoster postherpetic neuralgia simian virus
      #4
      Kenneth E Schmader
      herpes zoster postherpetic neuralgia veterans affairs
      #5
      STEPHEN E Straus
      chronic fatigue syndrome simplex virus autoimmune lymphoproliferative
      #6
      Richard J Whitley
      simplex virus herpes zoster central nervous

      Department of Medicine, The Medical University of South Carolina University Medical Center, Charleston, South Carolina | Department of Infectious Diseases, College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA | D

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.